Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Tyligand Bioscience logo — Innovative small molecule therapeutics for cancer and autoim...

Tyligand Bioscience

Innovative small molecule therapeutics for cancer and autoimmune disease treatment.

Founded 2018 4 employees Series A Biotechnology, Health Care

General Information

Company Name Tyligand Bioscience
Founded Year 2018
Employees 4
Industries Biotechnology, Health Care
Funding Stage Series A
Social

Get notified when Tyligand Bioscience moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Tyligand Bioscience

Tyligand Bioscience is a biotechnology company founded in 2018 with a focus on developing innovative small molecule therapeutics for cancer and autoimmune disease treatment. Their commitment to discovering and developing small molecule therapeutics has attracted significant investment, with the latest being a Series A investment on 08 July 2023. This round of funding was led by a consortium of investors including Calor Capital, Shengdi Investment, YF Capital, TaiKun Fund, Ming Bioventures, BOHE Angel Fund, CMS Capital. Tyligand Bioscience's unique approach and potential for impact in the biotechnology and healthcare industries have garnered notable attention from venture capital firms. Their mission to develop effective treatments for tumors and autoimmune disorders signifies a promising future in the field of healthcare innovation.

Taxonomy: small molecule therapeutics, cancer treatment, autoimmune disease treatment, drug discovery, pharmaceuticals, medicine, oncology, immunology, patient health, tumor targeting, health outcomes

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 7
Investor Investor
•••• •••• 		08 Jul 2023
Seed Round •••••• 1
Investor
01 Jan 2020

Tyligand Bioscience Alternatives & Competitors

Tyligand Bioscience vs
ImmunoBiome Inc.
ImmunoBiome Inc.

Microbiome-Targeted Therapeutics for Intractable Immune Diseases.

Tyligand Bioscience vs
Zerigo Health
Zerigo Health United States

A smart, convenient, cost-effective solution for treating chronic skin conditions like eczema and ps...

Series B
37 employees
Biopharma, Biotechnology
Tyligand Bioscience vs
ZaBeCor Pharmaceuticals
ZaBeCor Pharmaceuticals

Pioneering molecular advancements for asthma, allergies, and a spectrum of inflammatory and infectio...

Series Unknown
2 employees
Biotechnology, Health Care

FAQ About Tyligand Bioscience

Innovative small molecule therapeutics for cancer and autoimmune disease treatment.
Tyligand Bioscience was founded in 2018.
Tyligand Bioscience operates in the following industries: Biotechnology, Health Care.
Tyligand Bioscience has approximately 4 employees.
Tyligand Bioscience has completed 2 funding rounds. The latest funding stage is Series A.
Top alternatives and competitors to Tyligand Bioscience include ImmunoBiome Inc., Zerigo Health, ZaBeCor Pharmaceuticals, Biomarked, Thaumachron. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Tyligand Bioscience and ImmunoBiome Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Tyligand Bioscience and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy